Court dismisses lawsuit over drug imports

Share this article:

A U.S. district court judge has dismissed a lawsuit filed by several consumer groups that accused Pfizer, Merck GlaxoSmithKline and six other drugmakers of colluding to block American consumers from importing cheaper drugs from Canada.
The judge ruled that buying drugs in Canada for use in the U.S. is illegal, so an effort to stop it can't be a violation of federal antitrust law.
"Prescription drugs purchased in Canada by American consumers for personal use in the United States are misbranded if introduced into United States' commerce," and therefore are illegal, wrote U.S. District Judge Joan Erickson.
"The courts are not the proper forum to determine whether Canada or another country's prescription drug labels or symbols function in the same manner or offer the same protections as the United States' 'Rx only' symbol." Ericksen ruled.
A spokeswoman for GlaxoSmithKline told "(The judge's) finding that these medicines imported into the U.S. from Canada are illegal – that's really a very weighty decision for us. And the absolute dismissal of the federal antitrust claims is a very favorable outcome."
Other drugmakers named in the lawsuit include Abbott Laboratories, Eli Lilly, Novartis, Wyeth, Boehringer Ingelheim and AstraZeneca.
The consumer groups suing the drugmakers included individuals and groups including the Minnesota Senior Federation, United Senior Action of Indiana, the Massachusetts Senior Action Council and the Central Laborers Welfare Fund.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...